European Best Practice Guidelines 14-16 -: Inadequate response to epoetin

[11] Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance? [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (04) : 535 - 540

[12] DHONDT AW, 1995, NEPHROL DIAL TRANSPL, V10, P2107

[13] Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: Possible implications of angiotensin-converting enzyme inhibitors [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (02) : 396 - 397

[14] The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (08) : 1912 - 1916

[15] RESISTANCE TO ERYTHROPOIETIN IN IRON-OVERLOADED HEMODIALYSIS-PATIENTS CAN BE OVERCOME BY ASCORBIC-ACID ADMINISTRATION [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 : 44 - 47

[16] Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients [J]. NEPHRON, 1998, 78 (01): : 23 - 27

[17] Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients [J]. KIDNEY INTERNATIONAL, 1996, 50 (03) : 973 - 978

[18] Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (04) : 749 - 751

[19] Is there a role for adjuvant therapy in patients being treated with epoetin? [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 : 50 - 60

[20] Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy [J]. FREE RADICAL RESEARCH, 1999, 31 (03) : 211 - 216

[11] Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance? [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (04) : 535 - 540

[12] DHONDT AW, 1995, NEPHROL DIAL TRANSPL, V10, P2107

[13] Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: Possible implications of angiotensin-converting enzyme inhibitors [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (02) : 396 - 397

[14] The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (08) : 1912 - 1916

[15] RESISTANCE TO ERYTHROPOIETIN IN IRON-OVERLOADED HEMODIALYSIS-PATIENTS CAN BE OVERCOME BY ASCORBIC-ACID ADMINISTRATION [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 : 44 - 47

[16] Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients [J]. NEPHRON, 1998, 78 (01): : 23 - 27

[17] Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients [J]. KIDNEY INTERNATIONAL, 1996, 50 (03) : 973 - 978

[18] Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (04) : 749 - 751

[19] Is there a role for adjuvant therapy in patients being treated with epoetin? [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 : 50 - 60

[20] Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy [J]. FREE RADICAL RESEARCH, 1999, 31 (03) : 211 - 216